Leukemias, lymphomas, and other hematologic cancers:
Indications for: Pentostatin
Active hairy cell leukemia.
Adult Dosage:
Ensure adequate hydration. Give as IV bolus or infuse over 20–30 minutes after dilution. 4mg/m2 every other week. Reevaluate after 6 months; discontinue if complete or partial response not achieved; max duration of therapy 12 months. Withhold dose if ANC <200 cells/mm3; may resume when resolved.
Children Dosage:
Not recommended.
Pentostatin Warnings/Precautions:
Active infections; treat prior to initiating therapy. Withhold or discontinue therapy if severe rash or neurotoxicity develops. Renal impairment. Monitor and obtain CBCs, liver, and renal function before and during therapy. Pregnancy (Cat. D); avoid use. Nursing mothers: not recommended.
Pentostatin Classification:
Antimetabolite.
Pentostatin Interactions:
Concomitant fludarabine: not recommended. Potentiates vidarabine. Acute pulmonary toxicity and hypotension with carmustine, etoposide, and high dose cyclophosphamide (see literature).
Adverse Reactions:
GI upset, fever, rash, fatigue, leukopenia, pruritus, cough, myalgia, chills, headache, abdominal pain, anorexia, asthenia, stomatitis, rhinitis, dyspnea, anemia, pain, sweating, infections, thrombocytopenia.
How Supplied:
Single-dose vials—1
